

Small Cell Lung Cancer (SCLC) Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-13 | 180 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5499.00
- Five User License \$7499.00
- Corporate License \$9499.00

Report description:

Small Cell Lung Cancer (SCLC) Market Report and Forecast 2024-2032

Small Cell Lung Cancer (SCLC) Market Outlook

The small cell lung cancer (SCLC) market size in the 7 major markets is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032. The growth of the market can be attributed to the rising prevalence of small cell lung cancer (SCLC) across these markets.

Small Cell Lung Cancer (SCLC): Introduction

Small cell lung cancer is a rare and lethal lung cancer that grows aggressively. It can affect anyone, but people with a long history of smoking tobacco are most susceptible to SCLC. It can be treated with a high chance of living a healthy life if the disease is detected in the early stages. The only way one can prevent small cell lung cancer is by not smoking.

Small Cell Lung Cancer (SCLC) Market Analysis

The small cell lung cancer (SCLC) market demand is witnessing significant growth due to the increased prevalence of small cell lung cancer (SCLC) among people. The continuous comprehension by the FDA in closing a crucial gap of unmet needs is a major factor expected to be responsible for the growth of the market in the forecast period. For example, the US Food and Drug Administration (FDA) granted orphan drug designation (ODD) to REQORSA(R) immunogene therapy for the combination of its immunogene therapy REQORSA(R). It has been developed by a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. Such designations by the FDA are expected to result in innovation among biotech companies dedicated to developing treatments for people suffering from this disease, further bolstering the small cell lung cancer (SCLC) market growth.

Additionally, to find an appropriate treatment for this life-threatening disease, scientists are continuously engaged in research to discover therapeutics that could act effectively in the treatment or prevention of SCLC. Pharmaceutical companies are participating equally in these research activities. For example, Chugai Pharmaceutical Co., Ltd., Japan's pioneering research-based pharmaceutical company with strengths in biotechnology products, recently declared that their phase III BEAT-SC study, evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and platinum-based chemotherapy as a first-line

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

treatment for extensive-stage small cell lung cancer (ES-SCLC), met its primary endpoint of progression-free survival (P89uuFS).

Positive results from such studies stand fair chances to play a crucial role in the development of new therapeutics for effective treatment of SCLC provide better patient outcomes, and act as a catalyst in the demand for such treatments, propelling the market growth in the forecast period.

Small Cell Lung Cancer (SCLC) Market Segmentations

Market Breakup by Treatment

- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Others

Market Breakup by Route of Administration

- Oral
- Intravenous
- Others

Market Breakup by Gender

- Male
- Female

Market Breakup by End User

- Hospitals
- Homecare
- Specialty Centres
- Others

Market Breakup by Distribution Channel

- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy

Market Breakup by Region

- United States
- EU-4 and the United Kingdom
 - o□Germany
 - o□France
 - o□Italy
 - o□Spain
 - o□United Kingdom
- Japan

Small Cell Lung Cancer (SCLC) Market Overview

The market growth is driven by the increasing prevalence of small cell lung cancer (SCLC). The rising number of smokers across

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

the world and especially these 7 regions are the major reasons for the increased prevalence of this condition. Lung cancer is the second most diagnosed cancer worldwide. The market growth is further driven by ongoing research and innovations to bring new treatments for cures and diagnostics to enable early detection of this deadly disease. Such innovations and advancements are expected to exhibit an upward trajectory for the forecast cast and contribute to the small cell lung cancer (SCLC) market share. The increasing initiatives to spread awareness about the lethal nature of tobacco smoking are propelling the market further. Geographically, the United States is dominating the market due to the increased prevalence of the condition. It is estimated that approximately 14% of people who are diagnosed with lung cancer in the United States have SCLC. The market growth is further driven by the increased adaptation of advanced technologies and the availability of healthcare professionals who are aware of SCLC and its symptoms due to which early detection is possible in patients.

Small Cell Lung Cancer (SCLC) Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- []Teva Pharmaceutical Industries Ltd.
- []Sanofi
- []F. Hoffmann-La Roche Ltd.
- []Mylan N.V.
- []Pfizer Inc.
- []GSK plc
- []Novartis AG
- []Bayer AG
- []Sun Pharmaceutical Industries Ltd.
- []Aurobindo Pharma
- []Lupin
- []Merck & Co. Inc.
- []CLOVIS Oncology
- []Johnson & Johnson Private Limited
- []Lilly

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQ

- []What is the small cell lung cancer (SCLC) market forecast outlook for 2024-2032?

The market is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032, likely to be driven by the increased prevalence of small cell lung cancer (SCLC).

- []What are the major factors aiding the small cell lung cancer (SCLC) market demand?

The major factors driving the market demand include increased tobacco smoking, coupled with the increased prevalence of small cell lung cancer (SCLC) across the major markets.

- []What are the major small cell lung cancer (SCLC) market trends?

The high investments by the government and increasing initiatives by non-government organizations such as WHO to increase awareness about the disadvantages of tobacco smoking are among the major trends influencing the market growth.

- []What are the major regional markets for small cell lung cancer (SCLC), according to the EMR report?

The major regions of the market include the United States, EU-4 and the United Kingdom, and Japan. EU-4 includes Germany, France, Italy, and Spain.

- []What are the treatments available in the market?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Treatments for SCLC include chemotherapy, immunotherapy, targeted therapy, radiation therapy, and others.

-□What are the various routes of administration for SCLC treatments?

Various routes of administration include oral, intravenous, and others.

-□Which genders are affected by the condition?

The genders can be divided into male and female.

-□Who are the end users in the market?

End users in the market include hospitals, home care, specialty centers, and others.

-□What are the various distribution channels in the market?

Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies.

-□Who are the key players in the small cell lung cancer (SCLC) market?

Key players involved in the market are Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Mylan N.V., Pfizer Inc., GSK plc, Novartis AG, Bayer AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, Merck & Co. Inc., CLOVIS Oncology, Johnson & Johnson Private Limited, and Lilly.

Meta Description

The small cell lung cancer (SCLC) market size is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Small Cell Lung Cancer (SCLC) Overview
 - 3.1 Guidelines and Stages
 - 3.2 Pathophysiology
 - 3.3 Screening and Diagnosis
 - 3.4 Treatment Pathway
- 4 Patient Profile
 - 4.1 Patient Profile Overview
 - 4.2 Patient Psychology and Emotional Impact Factors
 - 4.3 Risk Assessment and Treatment Success Rate
- 5 Small Cell Lung Cancer (SCLC) Epidemiology Analysis - 7MM
 - 5.1 7MM Epidemiology Scenario Overview (2017-2032)
 - 5.2 United States Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
 - 5.3 EU-4 and United Kingdom Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
 - 5.3.1 Germany Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
 - 5.3.2 France Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
 - 5.3.3 Italy Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.3.4 Spain Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
 - 5.3.5 United Kingdom Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
- 5.4 Japan Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
- 6 Small Cell Lung Cancer (SCLC) Market Overview - 7MM
 - 6.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
 - 6.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
- 7 Small Cell Lung Cancer (SCLC) Market Landscape - 7MM
 - 7.1 Small Cell Lung Cancer (SCLC): Developers Landscape
 - 7.1.1 Analysis by Year of Establishment
 - 7.1.2 Analysis by Company Size
 - 7.1.3 Analysis by Region
 - 7.2 Small Cell Lung Cancer (SCLC) Product Landscape
 - 7.2.1 Analysis by Treatment
 - 7.2.2 Analysis by Route of Administration
- 8 Small Cell Lung Cancer (SCLC) Challenges and Unmet Needs
 - 8.1 Treatment Pathway Challenges
 - 8.2 Compliance and Drop-Out Analysis
 - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Small Cell Lung Cancer (SCLC) Market Dynamics
 - 10.1 Market Drivers and Constraints
 - 10.2 SWOT Analysis
 - 10.3 Porter's Five Forces Model
 - 10.4 Key Demand Indicators
 - 10.5 Key Price Indicators
 - 10.6 Industry Events, Initiatives, and Trends
 - 10.7 Value Chain Analysis
- 11 Small Cell Lung Cancer (SCLC) Market Segmentation - 7MM
 - 11.1 Small Cell Lung Cancer (SCLC) Market by Diagnosis
 - 11.1.1 Market Overview
 - 11.1.2 Imaging Tests
 - 11.1.3 Pulmonary Function Test
 - 11.1.4 Lung Tissue Analysis
 - 11.1.5 Others
 - 11.2 Small Cell Lung Cancer (SCLC) Market by Treatment
 - 11.2.1 Market Overview
 - 11.2.2 Chemotherapy
 - 11.2.3 Immunotherapy
 - 11.2.4 Targeted Therapy
 - 11.2.5 Radiation Therapy
 - 11.2.6 Others
 - 11.3 Small Cell Lung Cancer (SCLC) Market by Route of Administration
 - 11.3.1 Market Overview
 - 11.3.2 Oral
 - 11.3.3 Intravenous
 - 11.3.4 Others
 - 11.4 Small Cell Lung Cancer (SCLC) Market by Gender

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.4.1 Market Overview
- 11.4.2 Male
- 11.4.3 Female
- 11.5 Small Cell Lung Cancer (SCLC) Market by End User
 - 11.5.1 Market Overview
 - 11.5.2 Hospitals
 - 11.5.3 Homecare
 - 11.5.4 Specialty Centres
 - 11.5.5 Others
- 11.6 Small Cell Lung Cancer (SCLC) Market by Distribution Channel
 - 11.6.1 Market Overview
 - 11.6.2 Hospital Pharmacy
 - 11.6.3 Online Pharmacy
 - 11.6.4 Retail Pharmacy
- 11.7 Small Cell Lung Cancer (SCLC) Market by Region
 - 11.7.1 Market Overview
 - 11.7.2 United States
 - 11.7.3 EU-4 and the United Kingdom
 - 11.7.3.1 Germany
 - 11.7.3.2 France
 - 11.7.3.3 Italy
 - 11.7.3.4 Spain
 - 11.7.3.5 United Kingdom
 - 11.7.4 Japan
- 12 United States Small Cell Lung Cancer (SCLC) Market
 - 12.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
 - 12.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
 - 12.3 Small Cell Lung Cancer (SCLC) Market by Type
 - 12.4 Small Cell Lung Cancer (SCLC) Market by Treatment Type
- 13 EU-4 and United Kingdom Small Cell Lung Cancer (SCLC) Market
 - 13.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
 - 13.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
 - 13.3 Germany Small Cell Lung Cancer (SCLC) Market Overview
 - 13.3.1 Small Cell Lung Cancer (SCLC) Market by Type
 - 13.3.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
 - 13.4 France Small Cell Lung Cancer (SCLC) Market Overview
 - 13.4.1 Small Cell Lung Cancer (SCLC) Market by Type
 - 13.4.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
 - 13.5 Italy Small Cell Lung Cancer (SCLC) Market Overview
 - 13.5.1 Small Cell Lung Cancer (SCLC) Market by Type
 - 13.5.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
 - 13.6 Spain Small Cell Lung Cancer (SCLC) Market Overview
 - 13.6.1 Small Cell Lung Cancer (SCLC) Market by Type
 - 13.6.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
 - 13.7 United Kingdom Small Cell Lung Cancer (SCLC) Market Overview
 - 13.7.1 Small Cell Lung Cancer (SCLC) Market by Type
 - 13.7.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14 Japan Small Cell Lung Cancer (SCLC) Market
 - 14.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
 - 14.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
 - 14.3 Small Cell Lung Cancer (SCLC) Market by Type
 - 14.4 Small Cell Lung Cancer (SCLC) Market by Treatment Type
- 15 Regulatory Framework
 - 15.1 Regulatory Overview
 - 15.1.1 US FDA
 - 15.1.2 EU EMA
 - 15.1.3 JAPAN PMDA
- 16 Patent Analysis
 - 16.1 Analysis by Type of Patent
 - 16.2 Analysis by Publication year
 - 16.3 Analysis by Issuing Authority
 - 16.4 Analysis by Patent Age
 - 16.5 Analysis by CPC Analysis
 - 16.6 Analysis by Patent Valuation
 - 16.7 Analysis by Key Players
- 17 Grants Analysis
 - 17.1 Analysis by year
 - 17.2 Analysis by Amount Awarded
 - 17.3 Analysis by Issuing Authority
 - 17.4 Analysis by Grant Application
 - 17.5 Analysis by Funding Institute
 - 17.6 Analysis by NIH Departments
 - 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
 - 18.1 Analysis by Trial Registration Year
 - 18.2 Analysis by Trial Status
 - 18.3 Analysis by Trial Phase
 - 18.4 Analysis by Therapeutic Area
 - 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
 - 19.1 Analysis by Funding Instances
 - 19.2 Analysis by Type of Funding
 - 19.3 Analysis by Funding Amount
 - 19.4 Analysis by Leading Players
 - 19.5 Analysis by Leading Investors
 - 19.6 Analysis by Geography
- 20 Partnerships and Collaborations Analysis
 - 20.1 Analysis by Partnership Instances
 - 20.2 Analysis by Type of Partnership
 - 20.3 Analysis by Leading Players
 - 20.4 Analysis by Geography
- 21 Supplier Landscape
 - 21.1 Teva Pharmaceutical Industries Ltd.
 - 21.1.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 Sanofi
 - 21.2.1 Financial Analysis
 - 21.2.2 Product Portfolio
 - 21.2.3 Demographic Reach and Achievements
 - 21.2.4 Mergers and Acquisitions
 - 21.2.5 Certifications
- 21.3 F. Hoffmann-La Roche Ltd.
 - 21.3.1 Financial Analysis
 - 21.3.2 Product Portfolio
 - 21.3.3 Demographic Reach and Achievements
 - 21.3.4 Mergers and Acquisitions
 - 21.3.5 Certifications
- 21.4 Mylan N.V.
 - 21.4.1 Financial Analysis
 - 21.4.2 Product Portfolio
 - 21.4.3 Demographic Reach and Achievements
 - 21.4.4 Mergers and Acquisitions
 - 21.4.5 Certifications
- 21.5 Pfizer Inc.
 - 21.5.1 Financial Analysis
 - 21.5.2 Product Portfolio
 - 21.5.3 Demographic Reach and Achievements
 - 21.5.4 Mergers and Acquisitions
 - 21.5.5 Certifications
- 21.6 GSK plc
 - 21.6.1 Financial Analysis
 - 21.6.2 Product Portfolio
 - 21.6.3 Demographic Reach and Achievements
 - 21.6.4 Mergers and Acquisitions
 - 21.6.5 Certifications
- 21.7 Novartis AG
 - 21.7.1 Financial Analysis
 - 21.7.2 Product Portfolio
 - 21.7.3 Demographic Reach and Achievements
 - 21.7.4 Mergers and Acquisitions
 - 21.7.5 Certifications
- 21.8 Bayer AG
 - 21.8.1 Financial Analysis
 - 21.8.2 Product Portfolio
 - 21.8.3 Demographic Reach and Achievements
 - 21.8.4 Mergers and Acquisitions
 - 21.8.5 Certifications
- 21.9 Sun Pharmaceutical Industries Ltd.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 Aurobindo Pharma
 - 21.10.1 Financial Analysis
 - 21.10.2 Product Portfolio
 - 21.10.3 Demographic Reach and Achievements
 - 21.10.4 Mergers and Acquisitions
 - 21.10.5 Certifications
- 21.11 Lupin
 - 21.11.1 Financial Analysis
 - 21.11.2 Product Portfolio
 - 21.11.3 Demographic Reach and Achievements
 - 21.11.4 Mergers and Acquisitions
 - 21.11.5 Certifications
- 21.12 Merck & Co. Inc.
 - 21.12.1 Financial Analysis
 - 21.12.2 Product Portfolio
 - 21.12.3 Demographic Reach and Achievements
 - 21.12.4 Mergers and Acquisitions
 - 21.12.5 Certifications
- 21.13 CLOVIS Oncology
 - 21.13.1 Financial Analysis
 - 21.13.2 Product Portfolio
 - 21.13.3 Demographic Reach and Achievements
 - 21.13.4 Mergers and Acquisitions
 - 21.13.5 Certifications
- 21.14 Johnson & Johnson Private Limited
 - 21.14.1 Financial Analysis
 - 21.14.2 Product Portfolio
 - 21.14.3 Demographic Reach and Achievements
 - 21.14.4 Mergers and Acquisitions
 - 21.14.5 Certifications
- 21.15 Lilly
 - 21.15.1 Financial Analysis
 - 21.15.2 Product Portfolio
 - 21.15.3 Demographic Reach and Achievements
 - 21.15.4 Mergers and Acquisitions
 - 21.15.5 Certifications
- 22 Small Cell Lung Cancer (SCLC) Market- Distribution Model (Additional Insight)
 - 22.1 Overview
 - 22.2 Potential Distributors
 - 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
 - 25.1 Government Funded
 - 25.2 Private Insurance
 - 25.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Small Cell Lung Cancer (SCLC) Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-13 | 180 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5499.00
	Five User License	\$7499.00
	Corporate License	\$9499.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-02"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com